Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Prothena Corporation plc - Ordinary Shares
(NQ:
PRTA
)
9.930
-0.250 (-2.46%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
503,837
Open
10.04
Bid (Size)
9.940 (100)
Ask (Size)
9.950 (700)
Prev. Close
10.18
Today's Range
9.930 - 10.33
52wk Range
4.320 - 17.94
Shares Outstanding
45,047,449
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker
↗
November 12, 2025
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.
Via
Benzinga
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
From
Prothena Corporation plc
Via
Business Wire
Performance
YTD
-27.4%
-27.4%
1 Month
-1.9%
-1.9%
3 Month
+23.2%
+23.2%
6 Month
+47.9%
+47.9%
1 Year
-42.4%
-42.4%
More News
Read More
Prothena Corp PLC (NASDAQ:PRTA) Reports Q3 2025 Earnings and Key Pipeline Milestones
↗
November 06, 2025
Via
Chartmill
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Prothena Corporation plc
Via
Business Wire
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
9 Analysts Assess Prothena Corp: What You Need To Know
↗
August 05, 2025
Via
Benzinga
Earnings Scheduled For August 4, 2025
↗
August 04, 2025
Via
Benzinga
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 30, 2025
From
Prothena Corporation plc
Via
Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
↗
October 07, 2025
Via
Benzinga
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
October 01, 2025
From
Prothena Corporation plc
Via
Business Wire
A Glimpse of Prothena Corp's Earnings Potential
↗
August 01, 2025
Via
Benzinga
Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
September 02, 2025
Via
Benzinga
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
↗
August 29, 2025
Via
Benzinga
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 28, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
↗
August 28, 2025
Via
Benzinga
What 4 Analyst Ratings Have To Say About Prothena Corp
↗
August 28, 2025
Via
Benzinga
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
August 27, 2025
From
Prothena Corporation plc
Via
Business Wire
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful
↗
August 06, 2025
Via
Stocktwits
Topics
Earnings
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
August 06, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena Q2 Revenue Drops 97%
↗
August 05, 2025
Via
The Motley Fool
Topics
Intellectual Property
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
August 04, 2025
From
Prothena Corporation plc
Via
Business Wire
Prothena to Report Second Quarter 2025 Financial Results on August 4
July 28, 2025
From
Prothena Corporation plc
Via
Business Wire
8 Analysts Assess Prothena Corp: What You Need To Know
↗
June 20, 2025
Via
Benzinga
Prothena Shares Get A Boost After Company Slashes Workforce, Lowers 2025 Cash Burn Forecast
↗
June 20, 2025
Via
Stocktwits
Topics
Workforce
Prothena Announces Corporate Restructuring
June 18, 2025
From
Prothena Corporation plc
Via
Business Wire
Frequently Asked Questions
Is Prothena Corporation plc - Ordinary Shares publicly traded?
Yes, Prothena Corporation plc - Ordinary Shares is publicly traded.
What exchange does Prothena Corporation plc - Ordinary Shares trade on?
Prothena Corporation plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Prothena Corporation plc - Ordinary Shares?
The ticker symbol for Prothena Corporation plc - Ordinary Shares is PRTA on the Nasdaq Stock Market
What is the current price of Prothena Corporation plc - Ordinary Shares?
The current price of Prothena Corporation plc - Ordinary Shares is 9.930
When was Prothena Corporation plc - Ordinary Shares last traded?
The last trade of Prothena Corporation plc - Ordinary Shares was at 11/14/25 04:00 PM ET
What is the market capitalization of Prothena Corporation plc - Ordinary Shares?
The market capitalization of Prothena Corporation plc - Ordinary Shares is 447.32M
How many shares of Prothena Corporation plc - Ordinary Shares are outstanding?
Prothena Corporation plc - Ordinary Shares has 447M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.